Current Value
$0.721 Year Return
Current Value
$0.721 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IBN | -16.57% | $111.08B | +22.43% | 0.76% |
MOH | -15.38% | $17.97B | -13.21% | 0.00% |
MKC | -14.72% | $21.80B | +6.61% | 2.08% |
HDB | -14.27% | $194.29B | +17.22% | 1.05% |
MUSA | -13.08% | $9.51B | +14.23% | 0.38% |
CHD | -12.68% | $26.66B | +5.00% | 1.03% |
CSX | -12.50% | $56.05B | -18.34% | 1.73% |
CNC | -12.45% | $30.13B | -16.85% | 0.00% |
K | -11.88% | $28.46B | +45.70% | 2.75% |
MO | -11.29% | $96.57B | +35.61% | 6.83% |
NTZ | -11.14% | $54.74M | -20.73% | 0.00% |
MKTX | -10.64% | $7.95B | -1.91% | 1.34% |
KR | -10.56% | $48.68B | +16.46% | 1.77% |
ACIC | -10.45% | $549.55M | +9.94% | 0.00% |
ELV | -10.20% | $97.61B | -15.15% | 1.51% |
ABR | -9.98% | $2.23B | -9.39% | 14.69% |
HE | -9.83% | $1.88B | -1.18% | 0.00% |
AIV | -9.76% | $1.25B | +19.14% | 0.00% |
CMTL | -9.71% | $47.84M | -46.73% | 0.00% |
CME | -9.38% | $94.61B | +23.82% | 3.89% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -22.53% | $416.76M | 1.43% |
VIXY | -19.47% | $195.31M | 0.85% |
TAIL | -17.99% | $87.65M | 0.59% |
SMIN | -13.18% | $785.85M | 0.75% |
PIN | -11.94% | $227.66M | 0.78% |
EPI | -11.74% | $3.03B | 0.85% |
SGOV | -11.49% | $39.98B | 0.09% |
CCOR | -11.46% | $64.12M | 1.18% |
FLIN | -10.77% | $1.76B | 0.19% |
INDA | -10.41% | $8.84B | 0.62% |
GBIL | -10.10% | $6.30B | 0.12% |
SHV | -9.91% | $20.16B | 0.15% |
INDY | -9.66% | $640.27M | 0.89% |
JUCY | -9.53% | $306.51M | 0.6% |
ICSH | -8.52% | $5.64B | 0.08% |
CTA | -8.42% | $978.30M | 0.76% |
IBMP | -8.07% | $513.49M | 0.18% |
TBLL | -7.59% | $2.13B | 0.08% |
TFLO | -7.47% | $6.75B | 0.15% |
TPMN | -6.88% | $33.32M | 0.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BAH | <0.01% | $14.29B | -23.63% | 1.87% |
VKTX | -0.01% | $2.88B | -67.26% | 0.00% |
YOU | -0.01% | $2.55B | +38.43% | 1.80% |
CPK | -0.02% | $2.99B | +24.18% | 1.95% |
TEVA | -0.02% | $17.52B | +8.29% | 0.00% |
CWT | 0.03% | $2.89B | +7.23% | 2.28% |
YPF | -0.04% | $13.96B | +72.00% | 0.00% |
WBA | -0.04% | $9.67B | -39.57% | 6.80% |
CTO | 0.04% | $619.02M | +15.37% | 7.95% |
PAYX | -0.05% | $55.81B | +28.84% | 2.55% |
BBY | -0.06% | $16.01B | -4.51% | 5.87% |
PCT | -0.06% | $1.32B | +29.02% | 0.00% |
AMPH | 0.06% | $1.32B | -33.71% | 0.00% |
PRI | -0.07% | $9.66B | +16.69% | 1.30% |
TXO | -0.07% | $766.54M | +1.64% | 13.46% |
DFH | 0.08% | $2.13B | -47.08% | 0.00% |
UNP | 0.08% | $142.91B | -1.28% | 2.34% |
EVRG | 0.09% | $15.97B | +31.70% | 3.74% |
CLDX | 0.09% | $1.15B | -56.93% | 0.00% |
KO | -0.10% | $306.97B | +19.22% | 2.66% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ICHR | 27.62% | $768.81M | -41.29% | 0.00% |
AYI | 25.40% | $8.25B | +0.65% | 0.25% |
VIR | 25.15% | $888.69M | -33.13% | 0.00% |
APRE | 24.91% | $10.27M | -71.96% | 0.00% |
KLIC | 24.74% | $1.81B | -31.37% | 2.71% |
ADTN | 24.29% | $692.39M | +62.36% | 0.00% |
FUBO | 24.27% | $1.08B | +101.92% | 0.00% |
SNEX | 24.27% | $3.79B | +72.25% | 0.00% |
PSTG | 24.23% | $15.00B | -14.05% | 0.00% |
SANA | 23.99% | $366.79M | -82.21% | 0.00% |
TSM | 23.88% | $883.62B | +19.99% | 1.55% |
PYCR | 23.67% | $4.09B | +25.00% | 0.00% |
TPST | 23.58% | $34.56M | -85.17% | 0.00% |
WPRT | 23.55% | $58.70M | -48.80% | 0.00% |
SPHR | 23.26% | $1.20B | -30.65% | 0.00% |
LFUS | 23.20% | $4.86B | -17.85% | 1.62% |
LOGI | 23.11% | $12.80B | -5.21% | 1.88% |
JBLU | 22.57% | $1.78B | -26.42% | 0.00% |
FLS | 22.55% | $6.57B | +6.06% | 1.90% |
DAN | 22.40% | $1.99B | +9.88% | 3.27% |
Finnhub
Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data expected in 2H 2025Enrollment completed ahead of schedule in the...
Yahoo
ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meeti
Yahoo
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the period fro
Yahoo
Enrollment completed ahead of schedule in the first dose expansion cohortMomentum continues with first patient dosed in the second expansion cohortTopline results from the 40-patient dose expansion study expected in 1H 2026 Phase 1b dose escalation data expected to be presented in 2H 2025 ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of
Yahoo
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025. Details are as follows: Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceConference Date: Februar
Finnhub
ROCKVILLE - I-Mab , a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the Company has been informed...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SOYB | -0.12% | $26.08M | 0.22% |
SHY | 0.17% | $22.85B | 0.15% |
GCOR | 0.17% | $352.35M | 0.08% |
VUSB | 0.22% | $4.93B | 0.1% |
MEAR | 0.28% | $949.23M | 0.25% |
CGSD | -0.32% | $1.09B | 0.25% |
UTWO | -0.34% | $377.39M | 0.15% |
AGGH | -0.44% | $317.82M | 0.29% |
TBIL | -0.54% | $5.39B | 0.15% |
CGMU | 0.58% | $3.01B | 0.27% |
FLMI | 0.58% | $613.41M | 0.3% |
FLDR | 0.58% | $775.30M | 0.15% |
NUBD | -0.58% | $412.78M | 0.16% |
XBIL | -0.59% | $706.15M | 0.15% |
IBTI | 0.63% | $982.00M | 0.07% |
FSTA | -0.65% | $1.30B | 0.084% |
KSA | -0.74% | $682.42M | 0.75% |
BSMR | -0.76% | $235.44M | 0.18% |
VDC | -0.87% | $7.46B | 0.09% |
PULS | 0.88% | $11.04B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 36.04% | $48.38M | 0.69% |
EFAA | 29.41% | $100.03M | 0% |
AIA | 29.15% | $740.06M | 0.5% |
IDHQ | 27.51% | $363.86M | 0.29% |
EMXF | 27.50% | $87.88M | 0.17% |
JEMA | 27.36% | $1.09B | 0.34% |
HEZU | 26.95% | $692.91M | 0.53% |
ESGE | 26.64% | $4.51B | 0.26% |
CGGO | 26.61% | $5.13B | 0.47% |
FNDE | 26.17% | $6.54B | 0.39% |
CWI | 25.91% | $1.71B | 0.3% |
IQDF | 25.90% | $634.29M | 0.47% |
DBEF | 25.87% | $7.78B | 0.35% |
HEFA | 25.60% | $7.70B | 0.35% |
CGXU | 25.58% | $3.34B | 0.54% |
EFG | 25.57% | $12.39B | 0.36% |
AAXJ | 25.55% | $2.49B | 0.72% |
GEM | 25.51% | $893.08M | 0.45% |
EYLD | 25.45% | $495.08M | 0.63% |
CNYA | 25.45% | $218.06M | 0.6% |